124 related articles for article (PubMed ID: 27956417)
21. Oritavancin, a new lipoglycopeptide antibiotic: results from a thorough QT study.
Darpo B; Lee SK; Moon TE; Sills N; Mason JW
J Clin Pharmacol; 2010 Aug; 50(8):895-903. PubMed ID: 20484618
[TBL] [Abstract][Full Text] [Related]
22. Laboratory testing of anticoagulants: the present and the future.
Favaloro EJ; Lippi G; Koutts J
Pathology; 2011 Dec; 43(7):682-92. PubMed ID: 22081129
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
Paccaly A; Ozoux ML; Chu V; Simcox K; Marks V; Freyburger G; Sibille M; Shukla U
Thromb Haemost; 2005 Dec; 94(6):1156-63. PubMed ID: 16411387
[TBL] [Abstract][Full Text] [Related]
24. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
25. Hump-nosed pit viper (Hypnale hypnale) envenoming causes mild coagulopathy with incomplete clotting factor consumption.
Maduwage K; Scorgie FE; Silva A; Shahmy S; Mohamed F; Abeysinghe C; Karunathilake H; Lincz LF; Gnanathasan CA; Isbister GK
Clin Toxicol (Phila); 2013 Aug; 51(7):527-31. PubMed ID: 23879180
[TBL] [Abstract][Full Text] [Related]
26. Evaluation and performance characteristics of the Q Hemostasis Analyzer, an automated coagulation analyzer.
Toulon P; Fischer F; Appert-Flory A; Jambou D
Thromb Res; 2014 May; 133(5):927-35. PubMed ID: 24650798
[TBL] [Abstract][Full Text] [Related]
27. Revisiting the effects of spectral interfering substances in optical end-point coagulation assays.
Seheult JN; Dalenberg D; Sridharan MR; Stuart M; Moericke K; Cardel L; Heikal N; Chen D; Pruthi RK
Int J Lab Hematol; 2021 Oct; 43(5):1181-1190. PubMed ID: 33455065
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the Q analyzer, a new cap-piercing fully automated coagulometer with clotting, chromogenic, and immunoturbidometric capability.
Kitchen S; Woolley A
Blood Coagul Fibrinolysis; 2013 Jan; 24(1):28-34. PubMed ID: 23249565
[TBL] [Abstract][Full Text] [Related]
29. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
Morishima Y; Kamisato C
Am J Clin Pathol; 2015 Feb; 143(2):241-7. PubMed ID: 25596250
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
31. Oritavancin: a review in acute bacterial skin and skin structure infections.
Syed YY; Scott LJ
Drugs; 2015 Nov; 75(16):1891-902. PubMed ID: 26464319
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects.
Bhavnani SM; Owen JS; Loutit JS; Porter SB; Ambrose PG
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):95-102. PubMed ID: 15474317
[TBL] [Abstract][Full Text] [Related]
33. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
[TBL] [Abstract][Full Text] [Related]
34. Impact of different storage times at room temperature of unspun citrated blood samples on routine coagulation tests results. Results of a bicenter study and review of the literature.
Toulon P; Metge S; Hangard M; Zwahlen S; Piaulenne S; Besson V
Int J Lab Hematol; 2017 Oct; 39(5):458-468. PubMed ID: 28481034
[TBL] [Abstract][Full Text] [Related]
35. Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.
Zhang Y; Qian Q; Qian G; Sun G
Br J Biomed Sci; 2016 Jul; 73(3):134-139. PubMed ID: 27400196
[TBL] [Abstract][Full Text] [Related]
36. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of the factors associated with abnormal coagulation and prognosis
in patients with non-small cell lung cancer].
Li Y; Wei S; Wang J; Hong L; Cui L; Wang C
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):789-96. PubMed ID: 25404269
[TBL] [Abstract][Full Text] [Related]
38. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
[TBL] [Abstract][Full Text] [Related]
39. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.
Virtanen L; Salmela B; Leinonen J; Lemponen M; Huhtala J; Joutsi-Korhonen L; Lassila R
Blood Coagul Fibrinolysis; 2014 Sep; 25(6):597-603. PubMed ID: 24732174
[TBL] [Abstract][Full Text] [Related]
40. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
